Reported 2 days ago
Bausch Health Companies Inc. has announced its plan to acquire DURECT Corporation for approximately $63 million in cash, with potential additional payments based on sales milestones. The acquisition aims to advance the treatment of alcoholic hepatitis using DURECT's leading drug, larsucosterol, which has received Breakthrough Therapy Designation from the FDA. This move reinforces Bausch Health's focus on hepatology and their intention to progress larsucosterol into a Phase 3 program.
Source: YAHOO